The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
Abstract
Epigenetic regulation of gene transcription by small-molecule inhibitors of histone deacetylases (HDACs) is a novel cancer therapy. Vorinostat (suberoylanilide hydroxamic acid) is the first FDA-approved HDAC inhibitor for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL). Vorinostat was active against solid tumors and hematologic malignancies as intravenous and oral preparations in Phase I development. In two Phase II trials, vorinostat 400 mg/day was safe and effective with an overall response rate of 24-30% in refractory advanced patients with CTCL including large cell transformation and Sézary syndrome. The common side effects of vorinostat, which are similar in all studies, include gastrointestinal symptoms, fatigue and thrombocytopenia and the most common serious event was thrombosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Research works printed but not linked: 56
- 10.1056/NEJMra032810 · DOI · Paper page
- 10.1111/j.1468-3083.2004.00937.x · DOI · Paper page
- 10.1080/10428190410001693560 · doi:10.1080/10428190410001693560
- 10.1111/1523-1747.ep12363352 · DOI
- 10.1172/JCI200524826 · DOI
- BERGER, 2002, Blood, 99, 2929, 10.1182/blood.V99.8.2929 · doi:10.1182/blood.v99.8.2929
- 10.1182/blood.V100.9.3369 · DOI
- ROOK, 1997, Clin. Exp. Immunol, 107, 16
- 10.1182/blood-2006-06-025999 · DOI · Paper page
- 10.1111/j.0022-202X.2005.23925.x · DOI · Paper page
- 10.1200/JCO.2005.14.167 · DOI · Paper page
- 10.1038/sj.bjc.6603465 · DOI
- 10.1111/j.1600-0609.2005.00546.x · DOI
- 10.1016/j.jmb.2004.02.006 · DOI · Paper page
- 10.1186/1741-7007-4-24 · DOI
- 10.1146/annurev.biochem.73.011303.073651 · DOI · Paper page
- 10.1016/j.jmb.2004.02.006 · DOI · Paper page
- FURUMAI, 2002, Cancer Res, 62, 4916
- 10.1038/ncponc0106 · DOI · Paper page
- O’, 2005, Eur. J. Haematol. Suppl, 150
- BUTLER, 2000, Cancer Res, 60, 5165
- 10.1073/pnas.182372299 · DOI · Paper page
- 10.1002/jcb.20045 · DOI · Paper page
- 10.1038/sj.leu.2402535 · DOI · Paper page
- 10.1182/blood-2002-08-2675 · DOI · Paper page
- 10.1172/JCI200111537 · doi:10.1172/jci200111537 · Paper page
- 10.1016/j.exphem.2004.09.008 · DOI
- KELLY, 2003, Clin. Cancer Res, 9, 3578
- 10.1200/JCO.2005.01.9679 · DOI · Paper page
- GARCIA-MANERO, 2005, Blood, 106, 785a, 10.1182/blood.V106.11.785.785 · doi:10.1182/blood.v106.11.785.785
- 10.1002/ijc.21939 · DOI
- 10.1067/mjd.2002.118538 · DOI · Paper page
- 10.1002/ijc.21824 · DOI
- 10.1038/sj.onc.1203176 · DOI · Paper page
- DESAI, 2003, Anticancer Res, 23, 499
- 10.2174/1568011054866946 · DOI
- 10.1517/13543784.14.12.1497 · DOI · Paper page
- BUTLER, 2000, Cancer Res, 60, 5165
- 10.1073/pnas.180316197 · DOI · Paper page
- 10.1073/pnas.0307708100 · DOI · Paper page
- ROSATO, 2003, Mol. Cancer Ther, 2, 1273
- 10.1073/pnas.0408345102 · DOI · Paper page
- 10.1158/0008-5472.CAN-03-2629 · DOI · Paper page
- 10.1073/pnas.0408732102 · DOI · Paper page
- 10.1182/blood-2003-09-3068 · DOI · Paper page
- 10.4161/cc.4.4.1564 · DOI
- MEI, 2004, Int. J. Oncol, 25, 1509
- 10.1016/j.ctrv.2004.04.006 · DOI
- 10.1038/sj.leu.2403385 · DOI · Paper page
- 10.1517/14728222.8.5.409 · DOI · Paper page
- 10.1111/j.1365-2567.2005.02091.x · DOI · Paper page
- DUVIC, 2006, Blood, 108, 112a, 10.1182/blood.V108.11.112.112 · doi:10.1182/blood.v108.11.112.112
- OLSEN, 2006, ASCO Annual Meeting Proceedings, 24, 7500
- 10.1158/1078-0432.CCR-06-2672 · DOI · Paper page
- DUVIC, 2001, J. Clin. Oncol, 19, 2456, 10.1200/JCO.2001.19.9.2456 · DOI · Paper page
- 10.1038/nrd2133 · DOI · Paper page
Cited by
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
Carew, J. S., Giles, F. J., & Nawrocki, S. T. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.037 · Cited by 421
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Inside HDACs with more selective HDAC inhibitors
Roche, J., & Bertrand, P. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.047 · Cited by 312
Histone Deacetylases and Mechanisms of Regulation of Gene Expression
Chen, H. P., Zhao, Y. T., & Zhao, T. C. (2015) · Critical Reviews in Oncogenesis · doi:10.1615/critrevoncog.2015012997 · Cited by 306
Metadata
- Authors
- Duvic, M., & Vu, J.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2007-06-26
- Volume
- 16
- Issue
- 7
- Pages
- 1111-1120
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W1968568016
- Cited by
- 344
- References
- 3
- FWCI
- 26.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. https://app.cochat.ai/papers/10.1517/13543784.16.7.1111
- The paper
- Duvic, M., & Vu, J. (2007). Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.16.7.1111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.